PDF(Pubmed)
Abstract：
BACKGROUND: COVID-19 pandemic has changed the approach of dermatologists, with respect to management of numerous conditions, vitiligo being one of them. However, there is a lack of consensus on how to deal with patients of vitiligo, as we battle this pandemic.
OBJECTIVE: To conduct a questionnaire-based survey, amongst expert dermatologists; in order to understand the impact of COVID-19 on the management of vitiligo.
METHODS: An online semi-structured English questionnaire was prepared and the link was circulated among 50 pan-Indian expert dermatologists, through various platforms (snowball sampling). Confidentiality and anonymity were strictly maintained. Responses were analyzed at the end of the study and a consensus statement was generated.
RESULTS: 42.22% of the respondents believed that teleconsultation is adequate for the diagnosis and management of most cases of vitiligo. 64.44% were found to be comfortable in prescribing oral medications, even during the COVID-19 pandemic; of which 62% would prefer to prescribe systemic steroids; followed by 17%, 11%, 7%, and 3% who would prefer cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate, respectively. 64.44% respondents would recommend phototherapy in their office and 80% would prefer home-based phototherapy (PUVAsol or handheld NBUVB devices). 86.67% would prefer to stop the oral immunosuppressive drugs, till the COVID-19 RTPCR positive patients are tested negative.
CONCLUSIONS: The results are based on a survey of a small albeit selected group of dermatologists who decided on the currently available information on COVID-19. The same may change depending on the nature of further available information on the virus and its effect on how we manage the patients.
CONCLUSIONS: Cases for initial consultation may be seen physically, and those for follow-up may be scheduled for teleconsultation. Topical therapy may be used without any hesitation. Phototherapy may be best advised with either PUVAsol or home-based phototherapy units (handheld NBUVB devices). With regards to systemic immunosuppressives, oral minipulse therapy may be preferable in view of lesser requirement of monitoring. Surgery for vitiligo should be performed only if the psychological well-being is severely affected.
OBJECTIVE: To conduct a questionnaire-based survey, amongst expert dermatologists; in order to understand the impact of COVID-19 on the management of vitiligo.
METHODS: An online semi-structured English questionnaire was prepared and the link was circulated among 50 pan-Indian expert dermatologists, through various platforms (snowball sampling). Confidentiality and anonymity were strictly maintained. Responses were analyzed at the end of the study and a consensus statement was generated.
RESULTS: 42.22% of the respondents believed that teleconsultation is adequate for the diagnosis and management of most cases of vitiligo. 64.44% were found to be comfortable in prescribing oral medications, even during the COVID-19 pandemic; of which 62% would prefer to prescribe systemic steroids; followed by 17%, 11%, 7%, and 3% who would prefer cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate, respectively. 64.44% respondents would recommend phototherapy in their office and 80% would prefer home-based phototherapy (PUVAsol or handheld NBUVB devices). 86.67% would prefer to stop the oral immunosuppressive drugs, till the COVID-19 RTPCR positive patients are tested negative.
CONCLUSIONS: The results are based on a survey of a small albeit selected group of dermatologists who decided on the currently available information on COVID-19. The same may change depending on the nature of further available information on the virus and its effect on how we manage the patients.
CONCLUSIONS: Cases for initial consultation may be seen physically, and those for follow-up may be scheduled for teleconsultation. Topical therapy may be used without any hesitation. Phototherapy may be best advised with either PUVAsol or home-based phototherapy units (handheld NBUVB devices). With regards to systemic immunosuppressives, oral minipulse therapy may be preferable in view of lesser requirement of monitoring. Surgery for vitiligo should be performed only if the psychological well-being is severely affected.
摘要：
背景：COVID-19大流行改变了皮肤科医生的方法，关于众多条件的管理，白癜风就是其中之一。然而,关于如何处理白癜风患者缺乏共识，当我们与这场流行病作斗争时。
目的：进行问卷调查，在皮肤科专家中；为了了解COVID-19对白癜风管理的影响。
方法：准备了一份在线半结构化英语问卷，并在50位泛印度专家皮肤科医生中分发了该链接，通过各种平台（雪球采样）。严格保密和匿名。在研究结束时分析反应，并产生共识声明。
结果：42.22％的受访者认为远程会诊足以诊断和治疗大多数白癜风病例。64.44％的人在开口服药物时感到舒适，即使在COVID-19大流行期间；其中62%的人更愿意开全身性类固醇；其次是17%，11%,7%,3%的人更喜欢环孢菌素，硫唑嘌呤，霉酚酸酯，和甲氨蝶呤,分别。64.44％的受访者建议在办公室进行光疗，80％的受访者更喜欢基于家庭的光疗（PUVAsol或手持式NBUVB设备）。86.67%的人更愿意停止口服免疫抑制药物，直到COVID-19RTPCR阳性患者检测为阴性。
结论：结果是基于对一小部分皮肤科医生的调查，这些皮肤科医生根据目前可用的COVID-19信息做出了决定。根据病毒的进一步可用信息的性质及其对我们如何管理患者的影响，这种情况可能会发生变化。
结论：初次咨询的病例可以从身体上看到，后续的可能会安排远程会诊。可以毫不犹豫地使用局部治疗。最好建议使用PUVAsol或基于家庭的光疗单元（手持式NBUVB设备）进行光疗。关于全身性免疫抑制剂，考虑到较少的监测需求，口服小脉冲治疗可能是优选的。只有在心理健康受到严重影响的情况下才应进行白癜风手术。
目的：进行问卷调查，在皮肤科专家中；为了了解COVID-19对白癜风管理的影响。
方法：准备了一份在线半结构化英语问卷，并在50位泛印度专家皮肤科医生中分发了该链接，通过各种平台（雪球采样）。严格保密和匿名。在研究结束时分析反应，并产生共识声明。
结果：42.22％的受访者认为远程会诊足以诊断和治疗大多数白癜风病例。64.44％的人在开口服药物时感到舒适，即使在COVID-19大流行期间；其中62%的人更愿意开全身性类固醇；其次是17%，11%,7%,3%的人更喜欢环孢菌素，硫唑嘌呤，霉酚酸酯，和甲氨蝶呤,分别。64.44％的受访者建议在办公室进行光疗，80％的受访者更喜欢基于家庭的光疗（PUVAsol或手持式NBUVB设备）。86.67%的人更愿意停止口服免疫抑制药物，直到COVID-19RTPCR阳性患者检测为阴性。
结论：结果是基于对一小部分皮肤科医生的调查，这些皮肤科医生根据目前可用的COVID-19信息做出了决定。根据病毒的进一步可用信息的性质及其对我们如何管理患者的影响，这种情况可能会发生变化。
结论：初次咨询的病例可以从身体上看到，后续的可能会安排远程会诊。可以毫不犹豫地使用局部治疗。最好建议使用PUVAsol或基于家庭的光疗单元（手持式NBUVB设备）进行光疗。关于全身性免疫抑制剂，考虑到较少的监测需求，口服小脉冲治疗可能是优选的。只有在心理健康受到严重影响的情况下才应进行白癜风手术。
